Clinical trials: Alcohol Disorders
Hepatitis C
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for…
- Trial name
- ETHOS II (NCT03685045)
- Testing
- Campaign days
- Where
- 32 sites in Australia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Alcohol Liver Disease
Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence.
ALD is the most common cause of liver cirrhosis in western world. In patients with ALD persistent alcohol intake is associated with increased mortality while cessation of alcohol consumption improve survival.
- Trial name
- NCT06175507
- Testing
- Naltrexon, Baclofen
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Alcohol Use Disorder, Alcohol Abuse
tAN for Substance Use Disorder
The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse, Substance Use Disorders, Substance Use Disorders Alcohol Use Withdrawal State
- Trial name
- NCT07281261
- Testing
- Sparrow Ascent
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Antisocial Behavior
Multisystemic Therapy-Emerging Adults (MST-EA) for Substance Abuse
This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal…
- Trial name
- NCT03035877
- Testing
- Multisystemic Therapy-Emerging Adults, Enhanced Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 183 people
- Sponsor
- Chestnut Health Systems
Heavy Episodic Drinking, Problem Drinking
Greek Connections Study
The purpose of this study is to evaluate the feasibility and acceptability of an intervention aiming to reduce heavy episodic drinking and negative consequences from alcohol by increasing the availability of and engagement in…
- Conditions
- Heavy Episodic Drinking, Problem Drinking, College Student Drinking
- Trial name
- NCT07839026
- Testing
- Alcohol-free Social Activities Program
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- University of Washington
Fetal Alcohol Syndrome
In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions
This study aims to validate that PLGF is a biomarker of cerebral lesions and therefore of secondary developmental disorders and disabilities that will be best diagnosed at 2 and 6 years of age.
- Trial name
- ALCOBRAIN (NCT03371641)
- Testing
- ASQ parental questionnaire, Development scales, Scale of Conners
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Alcoholism
Individualized Assessment and Treatment for Alcoholism II
The object of this study is to develop a treatment for alcohol use disorders that is more effective than current CB treatments. Through a 2009 R-21 pilot project the investigators developed a cognitive-behavioral (CB) treatment…
- Trial name
- IATP2 (NCT03233802)
- Testing
- Individualized Assess & Treatment (IATP), Packaged Cognitive-Behavioral (PCBT), Case Management (CaseM)
- Where
- United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- UConn Health
Alcohol Use Disorder
Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
The purpose of this study is to evaluate the safety and efficacy of dutasteride in reducing drinking and heavy drinking in men and women with alcohol use disorder.
- Trial name
- NCT04098302
- Testing
- Dutasteride Capsules
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- UConn Health
Alcohol Use Disorder (AUD)
Medication Development in Alcoholism: Suvorexant Versus Placebo
The primary hypotheses under test are that alcohol dependent subjects treated with suvorexant will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under…
- Trial name
- NCT04229095
- Testing
- Suvorexant 20 mg
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- The Scripps Research Institute
Alcoholism
New Medications to Treat Alcohol Dependence
In the last decade, there has been an explosion of new knowledge of the neuroscientific basis of alcohol-seeking behavior. Briefly, medications that modulate mesolimbic dopamine pathways by facilitating gamma amino butyric…
- Trial name
- NCT00223639
- Testing
- Topiramate
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Bankole Johnson
Alcohol Dependence, Alcohol Use Disorder
Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users
Our primary aim is to assess the feasibility of initiating treatment in the ED with extended-release naltrexone (XR-NTX) plus care management (CM) vs.
- Trial name
- NCT02445339
- Testing
- XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NYU Langone Health
Addiction, Substance, Alcohol Use Disorder
Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)
The goal of this observational study is to validate the French version of the PAWSS scale in a population of patients with Alcohol Use Disorders.
- Conditions
- Addiction, Substance, Alcohol Use Disorder, Alcohol Dependence, Alcohol Withdrawal
- Trial name
- PAWSS-VF (NCT06675539)
- Testing
- French version PAWSS
- Where
- France
- Volunteers
- 545 people
- Sponsor
- Etablissement Public de Santé Barthélemy Durand
ALD - Alcoholic Liver Disease
Comparison of ALD, NASH, and Healthy Control Patients
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in…
- Trial name
- NCT03224949
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Substance Abuse, Substance Dependence
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
The purpose of this study is to determine whether drug-dependent adults who participate in a dual processing relapse prevention treatment protocol that allows for sensory-based exposure experiences over 10-weeks in outpatient…
- Conditions
- Substance Abuse, Substance Dependence, Alcohol Abuse, Drug Use
- Trial name
- NCT01320748
- Testing
- Dual Processing, Relapse Prevention
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Inova Health Care Services
Stress Disorders, Post-Traumatic, Intimate Partner Violence
Addressing the Health Concerns of VA Women With Sexual Trauma
Lifetime sexual trauma (ST) (i.e., behaviors that range from unwanted sexual touching to attempted or completed rape) is a significant social and public health problem among women Veterans.
- Conditions
- Stress Disorders, Post-Traumatic, Intimate Partner Violence, Alcohol-Related Disorders
- Trial name
- SHE (NCT02957747)
- Testing
- SHE
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- VISN 17 Center of Excellence
Stress Disorders, Post-Traumatic, Substance-Related Disorders
Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)
This treatment intervention trial is designed for men and women with substance dependence and comorbid Post-Traumatic Stress Disorder (PTSD).
- Trial name
- NCT01365247
- Testing
- Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure, Relapse Prevention Treatment, Active Monitoring Control Group
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- The City College of New York
Hypertension
TARGET BP I Clinical Trial
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group…
- Trial name
- TARGET BP I (NCT02910414)
- Testing
- Dehydrated alcohol
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Ablative Solutions, Inc.
Alcohol-Related Disorders, Alcohol Dependence
Acamprosate to Reduce Symptoms of Alcohol Withdrawal
This study will examine whether a new drug called acamprosate can be helpful for alcohol withdrawal, a result of drinking high amounts of alcohol for long periods of time.
- Conditions
- Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
- Trial name
- NCT00106106
- Testing
- NMR-spectroscopy, Oral acamprosate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Alcoholic Intoxication, Chronic
Effect of Psychoeducation on Motivation to Change in Traumatized Alcoholics
Many people suffering from alcohol dependence have a history of exposure to stressful life situations, such as childhood physical or emotional misuse.
- Trial name
- NCT01323738
- Testing
- Psychoeducation
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Konstanz
Alcohol Use Disorders
The Effect of a Interdisciplinary Alcohol Cessation Intervention
The effect of alcohol interventions seems to be related to the intensity of the interventions. In this study the investigators will assess the effect of a interdisciplinary "booster session" in primary care, given to patients who…
- Trial name
- NCT01208571
- Testing
- "Booster session"
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Helse Stavanger HF
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.